Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07678645 Upadacitinib hemihydrate Primary Biliary Cholangitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07678645, evaluating Upadacitinib hemihydrate in Primary Biliary Cholangitis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07699380 Sodium Phenylbutyrate/Tauroursodeoxycholic Acid Type 1 Diabetes Immune Interven… Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07699380, evaluating Sodium Phenylbutyrate/Tauroursodeoxycholic Acid in Type 1 Diabetes Immune Intervention: trial design, endpoint strategy, sponsor context, benchmark readouts and development whi…
Latest Hotspot
8 min read
NCT07697456 FG-M701 Ulcerative Colitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07697456, evaluating FG-M701 in Ulcerative Colitis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07682896 GenSci098 Graves Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07682896, evaluating GenSci098 in Graves Disease: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07663422 Prednisone Autoimmune Hepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07663422, evaluating Prednisone in Autoimmune Hepatitis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07671222 Infliximab Sjögren Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07671222, evaluating Infliximab in Sjögren Disease: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07598825 Inebilizumab-cdon Autoimmune Hepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07598825, evaluating Inebilizumab-cdon in Autoimmune Hepatitis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07691970 Anifrolumab-FNIA Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07691970, evaluating Anifrolumab-FNIA in Systemic Lupus Erythematosus: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07672561 WD-890 Plaque Psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07672561, evaluating WD-890 in Plaque Psoriasis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07617597 Deuruxolitinib Phosphate Alopecia Areata Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07617597, evaluating Deuruxolitinib Phosphate in Alopecia Areata: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07670546 Olokizumab Polymyalgia Rheumatica Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07670546, evaluating Olokizumab in Polymyalgia Rheumatica: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07682506 Tofacitinib etocomil Vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07682506, evaluating Tofacitinib etocomil in Vitiligo: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.